Literature DB >> 33814229

Lack of neonatal Fc receptor does not diminish the efficacy of the HSV-1 0ΔNLS vaccine against ocular HSV-1 challenge.

Daniel J J Carr1, Amanda N Berube2, Adrian Filiberti2, Grzegorz B Gmyrek2.   

Abstract

The neonatal Fc receptor (FcRn) is constitutively expressed in the cornea and is up-regulated in response to herpes simplex virus type 1 (HSV-1). Previously, we found targeting cornea FcRn expression by small interfering RNA-mediated knockdown reduced the local efficacy of HSV-1 0ΔNLS vaccinated C57BL/6 mice against ocular challenge with HSV-1. The current study was undertaken to evaluate the HSV-1 0ΔNLS vaccine efficacy in FcRn deficient (FcRn KO) mice challenged with HSV-1. Whereas there was little neutralizing antibody detected in the serum of HSV-1 0ΔNLS vaccinated FcRn KO mice, these mice exhibited the same degree of protection against ocular challenge with HSV-1 as wild type (WT) C57BL/6 mice as measured by cumulative survival, infectious virus shed or retained in tissue, and corneal pathology including opacity and neovascularization. Mock-vaccinated FcRn KO mice were found to be more sensitive to ocular HSV-1 infection compared to mock-vaccinated (WT) mice in terms of cumulative survival and virus shedding. In addition, the FcRn KO mice generated significantly fewer effector (CD3+CD44+CD62L-) and central (CD3+CD44+CD62L+) memory CD8+ T cells compared to the WT mice 7 days post infection. Collectively, mock-vaccinated FcRn KO mice are susceptible to ocular HSV-1 infection but HSV-1 0ΔNLS vaccinated FcRn KO mice are resistant suggesting that in addition to the FcRn, other pathways are involved in mediating the protective effect of the HSV-1 0ΔNLS vaccine against subsequent HSV-1 challenge.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cornea; Herpes simplex virus type 1; Neonatal Fc receptor; Neovascularization; Vaccine

Mesh:

Substances:

Year:  2021        PMID: 33814229      PMCID: PMC8076088          DOI: 10.1016/j.vaccine.2021.03.075

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  60 in total

1.  Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn.

Authors:  E J Israel; D F Wilsker; K C Hayes; D Schoenfeld; N E Simister
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

2.  Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport.

Authors:  J L Leach; D D Sedmak; J M Osborne; B Rahill; M D Lairmore; C L Anderson
Journal:  J Immunol       Date:  1996-10-15       Impact factor: 5.422

Review 3.  Fcγ Receptor Function and the Design of Vaccination Strategies.

Authors:  Stylianos Bournazos; Jeffrey V Ravetch
Journal:  Immunity       Date:  2017-08-15       Impact factor: 31.745

4.  An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta.

Authors:  N E Simister; C M Story; H L Chen; J S Hunt
Journal:  Eur J Immunol       Date:  1996-07       Impact factor: 5.532

5.  Intracellular neutralization of viral infection in polarized epithelial cells by neonatal Fc receptor (FcRn)-mediated IgG transport.

Authors:  Yu Bai; Lilin Ye; Devin B Tesar; Haichen Song; Deming Zhao; Pamela J Björkman; Derry C Roopenian; Xiaoping Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-31       Impact factor: 11.205

Review 6.  Pathogenesis of herpes stromal keratitis--a focus on corneal neovascularization.

Authors:  Fernanda Giménez; Amol Suryawanshi; Barry T Rouse
Journal:  Prog Retin Eye Res       Date:  2012-08-07       Impact factor: 21.198

7.  Asymptomatic HLA-A*02:01-restricted epitopes from herpes simplex virus glycoprotein B preferentially recall polyfunctional CD8+ T cells from seropositive asymptomatic individuals and protect HLA transgenic mice against ocular herpes.

Authors:  Xavier Dervillez; Huma Qureshi; Aziz A Chentoufi; Arif A Khan; Elizabeth Kritzer; David C Yu; Oscar R Diaz; Chetan Gottimukkala; Mina Kalantari; Maria C Villacres; Vanessa M Scarfone; Denise M McKinney; John Sidney; Alessandro Sette; Anthony B Nesburn; Steven L Wechsler; Lbachir BenMohamed
Journal:  J Immunol       Date:  2013-10-07       Impact factor: 5.422

8.  Herpetic Eye Disease Study: A Controlled Trial of Topical Corticosteroids for Herpes Simplex Stromal Keratitis.

Authors:  Kirk R Wilhelmus; Lauren Gee; Walter W Hauck; Natalie Kurinij; Chandler R Dawson; Dan B Jones; Bruce A Barron; Herbert E Kaufman; Joel Sugar; Robert A Hyndiuk; Peter R Laibson; R Doyle Stulting; Penny A Asbell
Journal:  Ophthalmology       Date:  2020-04       Impact factor: 12.079

9.  Fibroblast growth factor-2 drives and maintains progressive corneal neovascularization following HSV-1 infection.

Authors:  H R Gurung; M M Carr; K Bryant; A J Chucair-Elliott; D Jj Carr
Journal:  Mucosal Immunol       Date:  2017-04-05       Impact factor: 7.313

10.  Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis.

Authors:  Shan K Naidu; Rafiq Nabi; Nagarjuna R Cheemarla; Brent A Stanfield; Paul J Rider; Nithya Jambunathan; Vladimir N Chouljenko; Renee Carter; Fabio Del Piero; Ingeborg Langohr; Konstantin G Kousoulas
Journal:  PLoS One       Date:  2020-02-06       Impact factor: 3.240

View more
  1 in total

Review 1.  Rational Design of Live-Attenuated Vaccines against Herpes Simplex Viruses.

Authors:  Brent A Stanfield; Konstantin G Kousoulas; Agustin Fernandez; Edward Gershburg
Journal:  Viruses       Date:  2021-08-18       Impact factor: 5.048

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.